Skip to main content

BMO Capital Remains a Hold on Novo Nordisk (NVO)

Tipranks - Tipranks - Wed Feb 25, 7:16AM CST

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk yesterday. The company’s shares closed yesterday at $39.63.

Claim 50% Off TipRanks Premium

Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Novo Nordisk, and Disc Medicine. According to TipRanks, Seigerman has an average return of 10.0% and a 55.39% success rate on recommended stocks.

In addition to BMO Capital, Novo Nordisk also received a Hold from Nordea Markets’s Martin Brenoe in a report issued today. However, on February 11, Berenberg Bank maintained a Buy rating on Novo Nordisk (NYSE: NVO).

See today’s best-performing stocks on TipRanks >>

Based on Novo Nordisk’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $78.43 billion and a net profit of $26.65 billion. In comparison, last year the company earned a revenue of $85.68 billion and had a net profit of $28.23 billion

Read More on NVO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).